Brooklyn ImmunoTherapeutics Inc
Brooklyn ImmunoTherapeutics Inc Stock, ASE:BTX
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.